These adverse effects can be reversed by peroxisome proliferator-activated receptor-gamma coactivator alpha (PGC1α) or peroxisome proliferator-activated receptor gamma agonists, enhancing renal function during obesity [44,45]. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.